



Cancer Immunotherapy: Advances and Future Prospects

Guest Editor:

Dr. Sumit Agarwal

Department of Pathology,
University of Alabama at
Birmingham, Birmingham, AL
35294, USA

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

In this special issue, the journal will focus on Cancer Immunotherapy, its advances and future prospects. The knowledge gained in the field of cancer immunotherapy is now being applied to unleash a robust immune response against tumors after years of painstaking research. This lead to better understand the interaction between tumors and the host immune system. However, challenges still exist in this field, includes better predicting patients response to therapy, finding targets for treatment of tumors lacking tumor-infiltrating lymphocytes also called as “immunologically cold tumors” and enhancing immunotherapy strategies by customizing immunotherapy approaches for each biological subtype. Therefore, we would like to have this special issue based on recent advances in the understanding of cancer and different immunotherapies. Adding new information on these subjects and addressing challenges and questions addressed above may lead to a better understanding of the immune response against cancer and may aid in developing cancer immunotherapies.

Dr. Sumit Agarwal
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)